Related references
Note: Only part of the references are listed.Review of P-gp Inhibition Data in Recently Approved New Drug Applications: Utility of the Proposed [I1]/IC50 and [I2]/IC50 Criteria in the P-gp Decision Tree
Sheetal Agarwal et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Long-lasting Inhibitory Effects of Cyclosporin A, but Not Tacrolimus, on OATP1B1-and OATP1B3-mediated Uptake
Yoshihisa Shitara et al.
DRUG METABOLISM AND PHARMACOKINETICS (2012)
The International Transporter Consortium: A Collaborative Group of Scientists From Academia, Industry, and the FDA
S-M Huang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Membrane transporters in drug development
Kathleen M. Giacomini et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Pharmacokinetics of the Oral Direct Renin Inhibitor Aliskiren in Combination With Digoxin, Atorvastatin, and Ketoconazole in Healthy Subjects: The Role of P-Glycoprotein in the Disposition of Aliskiren
Sujata Vaidyanathan et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
A regulatory viewpoint on transporter-based drug interactions
L. Zhang et al.
XENOBIOTICA (2008)
Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan
Anshul Gupta et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
Share Paper
